Literature DB >> 2350582

Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation.

K Atkinson1, M M Horowitz, R P Gale, D W van Bekkum, E Gluckman, R A Good, N Jacobsen, H J Kolb, A A Rimm, O Ringdén.   

Abstract

Chronic graft-versus-host disease (GVHD) is an important complication of bone marrow transplantation. We analyzed risk factors for chronic GVHD in 2,534 recipients of HLA-identical sibling transplants surviving at least 90 days after transplantation. The actuarial probability of developing chronic GVHD within three years posttransplant was 46% +/- 3% (95% confidence interval). The most important risk factor for chronic GVHD was acute GVHD. The 3-year probabilities of chronic GVHD were 28% +/- 3%, 49% +/- 5%, 59% +/- 6%, 80% +/- 9%, and 85% +/- 15% for persons with grades 0, I, II, III, and IV acute GVHD, respectively (P less than .0001). Among patients with no or grade I acute GVHD, recipient age greater than 20 years, use of non-T-cell depleted bone marrow, and alloimmune female donors for male recipients predicted a higher risk of chronic GVHD. When all three adverse risk factors were present, the probability of chronic GVHD was 62% among persons with no prior acute GVHD and 85% among those with grade I acute GVHD. Among patients with grade II through IV acute GVHD, no other risk factor predicted chronic GVHD. These data identify individuals who might benefit from treatment strategies aimed at changing the incidence of chronic GVHD.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2350582

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  56 in total

1.  Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice.

Authors:  Shoji Asakura; Daigo Hashimoto; Shuichiro Takashima; Haruko Sugiyama; Yoshinobu Maeda; Koichi Akashi; Mitsune Tanimoto; Takanori Teshima
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

2.  Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission.

Authors:  A Ruggeri; M Labopin; F Ciceri; M Mohty; A Nagler
Journal:  Bone Marrow Transplant       Date:  2015-12-14       Impact factor: 5.483

3.  Comparison of outcomes after transplantation of G-CSF-stimulated bone marrow grafts versus bone marrow or peripheral blood grafts from HLA-matched sibling donors for patients with severe aplastic anemia.

Authors:  Roland Chu; Ruta Brazauskas; Fangyu Kan; Asad Bashey; Christopher Bredeson; Bruce Camitta; Kuang-Yueh Chiang; Haydar Frangoul; Robert Peter Gale; Adrian Gee; Biju George; Frederick D Goldman; Thomas G Gross; Vikas Gupta; Gregory A Hale; Luis Isola; Alvaro Urbano Ispizua; Hillard Lazarus; Judith Marsh; James Russell; Mitchell Sabloff; Edmund K Waller; Mary Eapen
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-27       Impact factor: 5.742

4.  Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission.

Authors:  David B Miklos; Haesook T Kim; Katherine H Miller; Luxuan Guo; Emmanuel Zorn; Stephanie J Lee; Ephraim P Hochberg; Catherine J Wu; Edwin P Alyea; Corey Cutler; Vincent Ho; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Blood       Date:  2004-12-21       Impact factor: 22.113

5.  Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide.

Authors:  Christopher G Kanakry; Javier Bolaños-Meade; Yvette L Kasamon; Marianna Zahurak; Nadira Durakovic; Terry Furlong; Marco Mielcarek; Marta Medeot; Ivana Gojo; B Douglas Smith; Jennifer A Kanakry; Ivan M Borrello; Robert A Brodsky; Douglas E Gladstone; Carol Ann Huff; William H Matsui; Lode J Swinnen; Kenneth R Cooke; Richard F Ambinder; Ephraim J Fuchs; Marcos J de Lima; Borje S Andersson; Ravi Varadhan; Paul V O'Donnell; Richard J Jones; Leo Luznik
Journal:  Blood       Date:  2017-01-03       Impact factor: 22.113

6.  Older recipient age is paradoxically associated with a lower incidence of chronic GVHD in thymoglobulin recipients: a retrospective study exploring risk factors for GVHD in allogeneic transplantation with thymoglobulin GVHD prophylaxis.

Authors:  A B M Lim; J Storek; A Beligaswatte; M Collins; M Tacey; T Williamson; K Mason; E Li; M A Chaudhry; J A Russell; A Daly; J Szer; I Lewis; D Ritchie
Journal:  Bone Marrow Transplant       Date:  2015-02-02       Impact factor: 5.483

7.  Evaluation of prognostic factors among patients with chronic graft-versus-host disease.

Authors:  Jose A Pérez-Simón; Gabriel Afram; Rodrigo Martino; Jose L Piñana; Teresa Caballero-Velazquez; Olle Ringden; David Valcarcel; Dolores Caballero; Mats Remberger; Yanira de Paz; Jordi Sierra; Jesús San Miguel; Hans Hagglund
Journal:  Haematologica       Date:  2012-02-27       Impact factor: 9.941

8.  Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.

Authors:  Yoshihiro Inamoto; Fumihiko Kimura; Junya Kanda; Junichi Sugita; Kazuhiro Ikegame; Hideki Nakasone; Yasuhito Nannya; Naoyuki Uchida; Takahiro Fukuda; Kosuke Yoshioka; Yukiyasu Ozawa; Ichiro Kawano; Yoshiko Atsuta; Koji Kato; Tatsuo Ichinohe; Masami Inoue; Takanori Teshima
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

Review 9.  Genetics of allogeneic hematopoietic cell transplantation. Role of HLA matching, functional variation in immune response genes.

Authors:  John A Hansen; Effie W Petersdorf; Ming-Tseh Lin; Steven Wang; Jason W Chien; Barry Storer; Paul J Martin
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

10.  The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.

Authors:  Olle Ringdén; Steven Z Pavletic; Claudio Anasetti; A John Barrett; Tao Wang; Dan Wang; Joseph H Antin; Paolo Di Bartolomeo; Brian J Bolwell; Christopher Bredeson; Mitchell S Cairo; Robert P Gale; Vikas Gupta; Theresa Hahn; Gregory A Hale; Jorg Halter; Madan Jagasia; Mark R Litzow; Franco Locatelli; David I Marks; Philip L McCarthy; Morton J Cowan; Effie W Petersdorf; James A Russell; Gary J Schiller; Harry Schouten; Stephen Spellman; Leo F Verdonck; John R Wingard; Mary M Horowitz; Mukta Arora
Journal:  Blood       Date:  2008-12-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.